China's TaiMed Biologics has won the FDA's breakthrough therapy designation for its HIV therapy, ibalizumab (TMB-355), making it apparently the first Chinese med to get onto the list.
It turns out the GlaxoSmithKline whistleblowers who blew the top off the China corruption scandal had hundreds of copycats later on.
China's Tianyin Pharmaceutical may be in danger of being de-listed from the New York Stock Exchange for failing to file its latest quarterly report on time.
Various recent reports covering the near-term and long-term outlook for the pharmaceutical industry in Asia paint a positive picture with increased revenues coming from the generics and biosimilars industries along with products as specific as human insulin from China.
American businesses, including members of the pharmaceutical industry, appear to be less sanguine about their prospects of doing business or expanding it in China.
A cross-section of pharmaceutical industry players in China has objected to the steep price cuts of as much as 50% in a late January tender process in China's Hunan province.
China FDA has issued draft guidelines on changes to good clinical practice guidelines that cover 34 provisions, including the use of outsourced partners in China that are generally in line with international aims of harmonization.
India drug authorities are working on plans to increase the nation's capacity to produce its own bulk drugs in an effort to reduce its drug industry's dependence on imports, mainly from China.
The Indian government is expected to announce new strategies to bolster its bulk drug manufacturing capacity as part of an effort to reduce the country's dependency on Chinese API imports.
China sequencing giant BGI has had studies published recently having to do with things as deep as detecting novo mutations responsible for most genetic diseases to something as ordinary, yet important, as a prenatal genetic test it calls NIFTY that is nearly 100% accurate.